Drug Development Funnel: What I Learnt Building One From Scratch

Key Takeaways

• Failures, not successes, drive the billion‑dollar drug development cost.
• Pre‑clinical spend (~$430 M) rivals Phase III trial expenses per drug.
• Only 29% of Phase II candidates reach Phase III, mainly due to efficacy gaps.
• Early efficacy signals can reduce costly late‑stage failures.
• Biotech acquisitions price in the hidden cost of dozens of failed peers.

Pulse Analysis

The drug‑development funnel has become a staple illustration for investors and scientists alike, but its true lesson lies in the economics of failure. While headlines cite a $2‑$3 billion price tag for a new molecule, that figure aggregates the out‑of‑pocket spend on every candidate that never reaches the market. By visualizing the attrition from 22 nominated compounds to a single approved drug, the plot forces a shift in perspective: the cost of innovation is a portfolio expense, not a line‑item for a lone success.

Pre‑clinical research, often omitted from cost debates, accounts for roughly $430 million per approved therapy—comparable to the $255 million typically spent on a Phase III trial. Yet the steepest attrition occurs in Phase II, where only about one‑third of candidates survive, largely because efficacy cannot be reliably predicted before human testing. This creates a paradox: safety filters catch early toxicities cheaply, but efficacy gaps surface late, after substantial capital has been deployed. Companies that invest in robust translational biomarkers and adaptive trial designs can capture efficacy signals earlier, reducing the financial shock of Phase II failures and preserving pipeline value.

For investors and acquirers, the funnel underscores that a high‑valued biotech deal is effectively buying the collective risk‑pool of an entire target class. The purchase price embeds not just the winner’s R&D spend but also the sunk costs of countless unseen competitors. Recognizing this hidden portfolio cost encourages more disciplined valuation models and may drive a strategic shift toward collaborative platforms that share early data, spreading risk across the ecosystem. Ultimately, the funnel’s shape is intentional—fail fast, fail cheap—but tightening the early gates could lower overall spend, accelerate patient access, and improve the industry's return on R&D investment.